Bristol-Myers Squibb spent Q3 competing in a couple of hot market races--and for that, it needed more ad dollars.
Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.
Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing on the cake? The company didn't need to shell out on patient education to get them there.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.
For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
Portola Pharmaceuticals has laid out the last batch of Phase III data on its "breakthrough" anti-anticoagulant andexanet alfa, filling in the numbers that will be reviewed by regulators considering the biotech's upcoming pitch for marketing approval. And right alongside that announcement comes the latest numbers from Boehringer Ingelheim's breakthrough program for idarucizumab, which is already under review as an antidote to its blockbuster Pradaxa.
Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.
Bristol-Myers Squibb and Pfizer got a positive recommendation from the U.K.'s cost gatekeeper for its new-age clot-fighter Eliquis, giving the companies a boost as they chase $3 billion in sales for the drug and compete with rivals Pradaxa and Xarelto.
What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking it out in the marketplace for a while now.
According to FirstWord Pharma, over the past four quarters, the 50 biggest-growing drugs delivered an absolute sales increase of $31 billion to their makers. While the top 5 slots on FWP 's list are filled with a who's who of recent, high-powered launches, AbbVie stalwart Humira is right up there with the new rollouts--and the list holds a few surprises lower down, too.